Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cancer statistics, 2013.CA Cancer J Clin. 2013; 63: 11-30
- Tavassoli F.A. Devilee P. World Health Organization classification of tumor. Pathology and genetics of tumors of the breast and female genital organs. IARC Press, Lyon (France)2003: 13-59
- Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study.Clin Cancer Res. 2010; 16: 6100-6110
- Biomarkers for the clinical management of breast cancer: international perspective.Int J Cancer. 2013; 133: 1-13
- ASCO-CAP guidelines for breast predictive factor testing: an update.Appl Immunohistochem Mol Morphol. 2011; 19: 499-500
- Molecular portraits of human breast tumours.Nature. 2000; 406: 747-752
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.Proc Natl Acad Sci U S A. 2001; 98: 10869-10874
- Breast cancer classification and prognosis based on gene expression profiles from a population-based study.Proc Natl Acad Sci U S A. 2003; 100: 10393-10398
- Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer.J Clin Oncol. 2013; 31: 203-209
- Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.Breast. 2012; 21: 50-57
- Breast cancer subtypes and the risk of local and regional relapse.J Clin Oncol. 2010; 28: 1684-1691
- Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.Ann Oncol. 2011; 22: 1736-1747
- Analysis of the potent prognostic factors in luminal-type breast cancer.J Breast Cancer. 2012; 15: 401-406
- Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.J Natl Cancer Inst. 2009; 101: 736-750
- Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures.Breast Cancer Res. 2008; 10: R65
- Molecular subclasses of breast cancer: how do we define them? the IMPAKT 2012 Working Group Statement.Ann Oncol. 2012; 23: 2997-3006
- Prognostic impact of Ki-67 labeling indices with 3 different cutoff values, histological grade, and nuclear grade in hormone-receptor-positive, HER2-negative, node-negative invasive breast cancers.Breast Cancer. 2013; ([Epub ahead of print])
- The molecular portraits of breast tumors are conserved across microarray platforms.BMC Genomics. 2006; 7: 96
- An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers.Breast Cancer Res Treat. 2010; 121: 575-589
- Presenting features of breast cancer differ by molecular subtype.Ann Surg Oncol. 2009; 16: 2705-2710
- Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.J Clin Oncol. 2009; 27: 2962-2969
- 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.Lancet. 2007; 369: 29-36
- HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.J Natl Cancer Inst. 2008; 100: 14-20
- HER2 and response to paclitaxel in node-positive breast cancer.N Engl J Med. 2007; 357: 1496-1506
- HER-2 and topoisomerase II as predictors of response to chemotherapy.J Clin Oncol. 2008; 26: 736-744
- Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy.Cancer. 2007; 110: 1687-1696
- Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.J Clin Oncol. 2008; 26: 2373-2378
- Metastatic behavior of breast cancer subtypes.J Clin Oncol. 2010; 28: 3271-3277
- Subtypes of breast cancer show preferential site of relapse.Cancer Res. 2008; 68: 3108-3114
- Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.Mod Pathol. 2006; 19: 264-271
- Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research.Cancer Treat Rev. 2010; 36: 206-215
- Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.JAMA. 2006; 295: 2492-2502
- Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.Breast Cancer Res. 2010; 12: R68
- Identification of molecular apocrine breast tumours by microarray analysis.Oncogene. 2005; 24: 4660-4671
- Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers.Int J Clin Exp Pathol. 2009; 2: 444-455
- Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies.Cancer. 2003; 98: 703-711
- HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability.Cancer Cell. 2004; 6: 517-527
- Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma.Proc Natl Acad Sci U S A. 1996; 93: 7673-7678
- Tubular carcinoma of the breast: further evidence to support its excellent prognosis.J Clin Oncol. 2010; 28: 99-104
- Outcome of special types of luminal breast cancer.Ann Oncol. 2012; 23: 1428-1436
- Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome.Clin Breast Cancer. 2013; 13: 31-39
- Refinement of breast cancer classification by molecular characterization of histological special types.J Pathol. 2008; 216: 141-150
- Invasive lobular breast cancer: subtypes and outcome.Breast Cancer Res Treat. 2012; 133: 713-723
- Genetic up-regulation and overexpression of PLEKHA7 differentiates invasive lobular carcinomas from invasive ductal carcinomas.Hum Pathol. 2012; 43: 1902-1909
- Lobular invasive carcinoma of the breast is a molecular entity distinct from luminal invasive ductal carcinoma.Eur J Cancer. 2010; 46: 2399-2407
- Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation.Hum Pathol. 1992; 23: 655-662
- Pleomorphic lobular carcinoma: morphology, immunocytochemistry and molecular analysis.Am J Surg Pathol. 2000; 24: 1650-1656
- Pleomorphic lobular carcinoma: a distinctive clinical and molecular breast cancer type.Histopathology. 2012; 61: 365-377
- Is pleomorphic lobular carcinoma really a distinct clinical entity?.J Surg Oncol. 2008; 98: 314-317
- Infiltrating cribriform carcinoma of the breast: a distinctive clinicopathologic entity.Hum Pathol. 1990; 21: 333-338
- Microarray comparative genomic hybridization analysis of tubular breast carcinoma shows recurrent loss of the CDH13 locus on 16q.Hum Pathol. 2008; 39: 1621-1629
- Endocrine differentiation in mucoid carcinoma of the breast.Histopathology. 1980; 4: 613-630
- Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type.Mod Pathol. 2009; 22: 1401-1414
- Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type.J Pathol. 2010; 222: 282-298
- Immunophenotypic and genomic characterization of papillary carcinomas of the breast.J Pathol. 2012; 226: 427-441
- Clinicopathologic characteristics and molecular subtypes of invasive papillary carcinoma of the breast: a large case study.J Cancer Res Clin Oncol. 2013; 139: 77-84
- Breast carcinoma with micropapillary features: clinicopathologic study and long-term follow-up of 100 cases.Int J Surg Pathol. 2008; 16: 155-163
- Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast.J Pathol. 2008; 215: 398-410
- Characteristic morphology of invasive micropapillary carcinoma of the breast: an immunohistochemical analysis.Jpn J Clin Oncol. 2010; 40: 781-787
- Invasive micropapillary carcinoma of the breast is associated with chromosome 8 abnormalities detected by comparative genomic hybridization.Hum Pathol. 2002; 33: 628-631
- Immunohistochemically defined subtypes and outcome of apocrine breast cancer.Clin Breast Cancer. 2013; 13: 95-102
- Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.Jpn J Clin Oncol. 2012; 42: 375-386
- Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.Cancer Res. 2009; 69: 4116-4124
- Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis.Breast Cancer Res Treat. 2009; 117: 273-280
- Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas.J Pathol. 2010; 220: 562-573
- Medullary carcinoma of the breast: a population-based perspective.Med Oncol. 2011; 28: 738-744
- Risk of mortality by histologic type of breast cancer in the United States.Hormones & cancer. 2010; 1: 156-165
- Clinicopathologic features and long-term outcome of patients with medullary breast carcinoma managed with breast-conserving therapy (BCT).International Journal of Radiation Oncology, Biology, Physics. 2005; 62: 1040-1047
- Typical medullary carcinoma of the breast: a clinical and pathological analysis of 52 cases.Journal of Surgical Oncology. 1995; 60: 89-94
- Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up.Cancer. 1977; 40: 1365-1385
- Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers.Cancer Res. 2006; 66: 4636-4644
- Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity.Breast Cancer Res. 2007; 9: R24
- Breast carcinoma in children.JAMA. 1966; 195: 388-390
- Secretory carcinoma of the breast in adults.Am J Surg Pathol. 1980; 4: 465-470
- Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum.Mod Pathol. 2009; 22: 291-298
- Genomic profile of a secretory breast cancer with an ETV6-NTRK3 duplication.J Clin Pathol. 2009; 62: 604-612
- Secretory breast carcinoma: unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression.Arch Pathol Lab Med. 2011; 135: 1606-1610
- Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms.Mod Pathol. 2011; 24: 1169-1176
- Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers.J Pathol. 2012; 226: 84-96
- Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck.Proc Natl Acad Sci U S A. 2009; 106: 18740-18744
- Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study.Cancer. 2005; 103: 1778-1784
- Biology of ductal carcinoma in situ classification based on biologic potential.Am J Clin Oncol. 2006; 29: 305-310
- Distribution of estrogen receptor in ductal carcinoma in situ of the breast.Surgery. 1993; 113: 134-137
- Potential value of hormone receptor assay in carcinoma in situ of breast.Am J Clin Pathol. 1990; 94: 533-537
- Immunohistochemical detection of oestrogen receptors in ductal carcinoma in situ of the breast.Eur J Surg Oncol. 1996; 22: 578-582
- Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast.Eur J Cancer. 2003; 39: 622-630
- p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein.Hum Pathol. 1993; 24: 463-468
- Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution.Clin Cancer Res. 2008; 14: 370-378
- The molecular journey from ductal carcinoma in situ to invasive breast cancer.Cancer. 2008; 112: 2130-2142
- The clinical behavior of breast carcinoma is probably determined at the preinvasive stage (ductal carcinoma in situ).Cancer. 1997; 80: 1740-1745
- The effect of DCIS grade on rate, type and time to recurrence after 15 years of follow-up of screen-detected DCIS.Br J Cancer. 2012; 106: 1611-1617
- The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesions.Breast Cancer Res. 2003; 5: 313-319
- Is there a low-grade precursor pathway in breast cancer?.Ann Surg Oncol. 2012; 19: 1115-1121
- Molecular characterization of the tumor microenvironment in breast cancer.Cancer Cell. 2004; 6: 17-32
- Gene expression profiles of human breast cancer progression.Proc Natl Acad Sci U S A. 2003; 100: 5974-5979
- Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia.Breast Cancer Res Treat. 2012; 133: 1009-1024
Article info
Identification
Copyright
© 2013 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
